Johnson And Johnson India

Johnson & Johnson beat first-quarter expectations, as growth in the health care giant's home market helped counter another revenue hit overseas from a strong dollar. The health care giant booked a USD 68 million loss on a one-time charge in the quarter, and revenue grew more than 5 per cent to USD 24.75 billion, which was better than anticipated. Adjusted earnings totalled USD 2.68 per share, topping Wall Street projections for per-share earnings of USD 2.50, according to a survey by FactSet. Johnson & Johnson sells prescription drugs and medical devices. It is splitting off its consumer health business, which includes well-known products like BandAids. The company expects to complete the separation this year. Sales in the US grew nearly 10 per cent to USD 12.52 billion in the quarter, while international sales climbed nearly 2 per cent. A strong US dollar can affect sales for companies that do a lot of international business. They have to convert those sales into dollars when

The Bombay High Court on Wednesday quashed two orders passed by the Maharashtra government revoking the license of Johnson & Johnson company to manufacture, sell and distribute its baby powder products, terming them as stringent, unreasonable and unfair. A division bench of Justices Gautam Patel and S G Dige permitted the company to manufacture, sell and distribute the products. The bench passed its order on a petition filed by the company challenging two orders of the state government one dated September 15, 2022 cancelling the license and the second dated September 20, 2022 ordering it to immediately stop the manufacturing and sale of the baby powder product. The bench noted that while maintaining standards of quality and safety are of utmost importance for cosmetic products, at the same time it does not seem reasonable to shut down the whole manufacturing process when there is a slight deviation in one of the products. "The executive cannot use a hammer to kill an ant. Is it ..

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada

PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India.

(Reuters) - A New Jersey jury on Wednesday cleared Johnson & Johnson of liability in a lawsuit brought by a man who said that asbestos in the company's talcum powder products caused his mesothelioma.

A complaint was made to the National Anti-Profiteering Authority about two products - J&J Baby Shampoo and J&J Baby Powder

A group of patients who became victims of faulty hip implant by Johnson and Johnson (J&J) has written to Union Health Minister J.P. Nadda, rejecting the compensation formula accepted by the government stating it was done without consulting the stakeholders.

Johnson and Johnson faulty hip implant victims on Monday questioned the credibility of a panel formed by the Centre to determine the compensation amount for them, and alleged the entire process lacked transparency and followed no proper guidelines. In a letter written to Union Health Minister J P Nadda, a group over 30 victims also opposed involvement of the multi-national company in the process and threatened to boycott the entire exercise if their concerns are not addressed. The government had constituted the five-member Central Expert Committee to determine the quantum of compensation to be given to patients who received "faulty" hip implants, manufactured by DePuy International, a subsidiary of Johnson and Johnson. They patients questioned the credibility of the panel. They said they are distressed to see the government continuing its consultation with the J&J while the patients who suffered grievous injuries "have not been consulted even a single time". "Given the lack of ...

Aggrieved patients question impartiality of govt-appointed committee, call it 'one-sided'

The government issued a public notice recently asking patients to register with the state-level committees

An 11-member committee set up by the health ministry in February has concluded that J&J was at fault for 'serious medical negligence'

Johnson and Johnson India's paternal and maternal leave policies are at par with its global practice